Kemwell Biopharma

We are Bicycle Therapeutics, a clinical-stage biopharmaceutical company. We didn’t wait for the next advance against cancer. We created it.

Based on groundbreaking work conceived in the laboratory of Sir Greg Winter with the help of Professor Christian Heinis, we are pioneering the development of bicyclic peptides, or Bicycles® – a novel class of versatile, chemically synthesized medicines. Bicycles are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry. This constraint is designed to confer high affinity and selectivity, and the relatively large surface area presented by the molecule allows targets to be drugged that have historically been intractable to non-biological approaches. Bicycles represent a unique therapeutic class, combining the pharmacological properties normally associated with a biologic with the manufacturing and pharmacokinetic advantages of a small molecule, yet with no signs of immunogenicity observed to date.

Bicycles can be used as Bicycle conjugates to deliver toxin payloads and to precisely target local immune activation within tumors and as Bicycle T-cell modulators, which activate cytotoxic T-cells while circumventing the limitations of antibody and biologic therapies and better enabling combination therapy. Our lead product candidate, BT1718, is a Bicycle toxin conjugate currently being investigated in a Phase I/IIa open label dose escalation and expansion clinical trial sponsored by Cancer Research UK. BT1718 targets Membrane Type 1 Matrix Metalloproteinase (MT1-MMP), also known as MMP-14, which is highly expressed in many solid tumors.

Our strategic collaborations are based on the ability of Bicycles to address a wide variety of targets. Through collaborations with AstraZeneca, Oxurion, Innovate UK and the Dementia Discovery Fund, we work with companies that have deep therapeutic expertise outside of oncology to enable us to more efficiently develop novel medicines for patients.

Since its founding in 1992, bioWORLD has established, maintained, and succeeded in its core mission to manufacture and supply high-quality molecular tools, biological reagents, and laboratory supplies to analytical laboratories, academia institutions, and research corporations globally. bioWORLD specializes in numerous product lines for the Life Sciences and Biotechnology industries. With product focuses including bioAffinity reagents for protein purification and proteomics research, recombinant proteins and synthetic peptides, plant, microbiological, animal, and yeast media, and many other fields. In addition, bioWORLD offers services including custom peptide synthesis and antibody production.

The company's headquarters are in Dublin, Ohio, with sales offices located across the globe. Through both in-house manufacturing and supply chain acquisitions, bioWORLD supplies products to biomedical and life sciences industries. In addition, we provide custom laboratory services and formulations for R&D in the biotechnology industry. bioWORLD is a growing company, with both domestic channel partners (i.e. Fisher Scientific, Spectrum Chemical, Thomas Scientific, etc.) as well as established international distribution partners in 45 countries.

We are ChemPartner, an innovative, full-service life science CRO/CDMO providing biopharmaceutical research with a global reach. We have evolved from a chemistry service provider to a company offering full-service drug discovery and development for both small and large molecules, supported by biology, pharmacology, DMPK, and exploratory toxicology.

We are dedicated to technically and strategically accomplishing the research initiatives of pharmaceutical and biotech companies worldwide. Our mission is to provide clients with the highest quality R&D services in a timely and cost-effective manner.

As a Contract Research Organization (CRO) ChemPartner has helped hundreds of clients take their small molecule and biologics projects from all stages of drug discovery to pre-clinical candidate selection and beyond. We provide assistance not only in laboratory settings but also intellectual input at various levels, such as project strategy, experimental study design, data interpretation, and source reports for regulatory filings.

As a Contract Development and Manufacturing Organization (CDMO), we offer pharmaceutical development and manufacturing services for small molecules and biologics. We provide one-stop services for overall process development and IND application support, with a quality system in compliance with ICH guidelines and the highest standards of the CFDA, FDA, and EMA. We have expanded our Biologics GMP manufacturing capacity in our new facility in Qidong, suitable for commercial drug substance or products.

ChemPartner is uniquely positioned to not only be a CRO/CDMO, but to be the most reliable pharmaceutical alliance partner providing intellectual contributions and exceptional technical expertise.

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. We provide contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. Our goal is to provide a trusted source for all your assay development and manufacturing needs.

We also assist clients in rapidly developing, manufacturing and commercializing point of care lateral flow, flow through and ELISA assays for any market segment. We develop using fluorescent, visual colloidal gold and paramagnetic labels, and high sensitivity, quantitative and reader-based tests are our specialty.

With the decades of experiences and our unique technologies, Creative Diagnostics prides itself on its commitment to providing its customers in research and industry the highest quality products and services.

Custom Biologics provide exceptional, high quality, customized assays to measure the functional properties of cellular and biotherapeutic drug candidates. We are a Health Canada audited, GMP-compliant, global service provider for functional testing of biotherapeutics, biosimilars and antibody drug conjugates.

For over 14 years our scientists have been designing and validating sophisticated bioanalytical assays, to characterize and measure the therapeutic potential of large and small molecule biotherapeutics.

Our work supports regulatory drug submission applications from biopharmaceutical companies throughout North America, Europe and Asia.

Great Science - It's at the heart of everything we do!